The vaccine developed by AstraZeneca in collaboration with Oxford University demonstrated 62% efficacy – a far cry from the 90% and over shown in the trials of two US and one Russian vaccine that were presented earlier.
The developers of Russia’s Sputnik V vaccine have suggested that AstraZeneca try an experimental regimen during a new round of its COVID-19 vaccine trials. In a tweet, they recommended using two different vaccines, the Sputnik V and AstraZeneca’s own inoculation that was developed in cooperation with Oxford University, to try to “boost the efficacy” of the coronavirus vaccine.
Continue reading https://sptnkne.ws/E3hA